Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

USA – Batch uniformity: FDA details testing approaches for continuous manufacturing, 3D printing

The US Food and Drug Administration (FDA) has issued draft guidance to assist manufacturers in complying with its good manufacturing practice (GMP) regulations under 21 CFR 211.110 governing batch uniformity for drug and biological products. The guidance specifically addresses methods for ensuring blend uniformity for products made through advanced manufacturing techniques, such as continuous manufacturing and 3D printing.
The guidance recommends the use of process models combined with in-process material testing to ensure the blend uniformity of drug products produced on a continuous manufacturing line.
Until this point, there has been limited FDA guidance on how manufacturers can assess blend uniformity for products that are made on a continuous manufacturing line or 3D printed.

The deadline for comments is 7 April 2025. More information on Regulatory Focus.


OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (25 mars 2025). USA – Batch uniformity: FDA details testing approaches for continuous manufacturing, 3D printing. ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/13kgf


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.